GR970100408A - Μεθοδοι προληψεως του καρκινου του μαστου - Google Patents

Μεθοδοι προληψεως του καρκινου του μαστου

Info

Publication number
GR970100408A
GR970100408A GR970100408A GR970100408A GR970100408A GR 970100408 A GR970100408 A GR 970100408A GR 970100408 A GR970100408 A GR 970100408A GR 970100408 A GR970100408 A GR 970100408A GR 970100408 A GR970100408 A GR 970100408A
Authority
GR
Greece
Prior art keywords
breast cancer
methods
preventing breast
preventing
administering
Prior art date
Application number
GR970100408A
Other languages
English (en)
Other versions
GR1003189B (el
Inventor
Janine Teri Scott
Jay Frederick Cohen
Ronald Keith Knickerbocker
Thomas Nikolaus Nickelsen
Stephen Robert Eckert
Ellen Joan Glusman
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR970100408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of GR970100408A publication Critical patent/GR970100408A/el
Publication of GR1003189B publication Critical patent/GR1003189B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
GR970100408A 1996-10-30 1997-10-29 Μεθοδοι προληψεως του καρκινου του μαστου GR1003189B (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (2)

Publication Number Publication Date
GR970100408A true GR970100408A (el) 1998-06-30
GR1003189B GR1003189B (el) 1999-09-01

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
GR970100409A GR970100409A (el) 1996-10-30 1997-10-29 Βελτιωσεις στην προληψη του καρκινου του μαστου και σε σχεση με αυτην
GR970100408A GR1003189B (el) 1996-10-30 1997-10-29 Μεθοδοι προληψεως του καρκινου του μαστου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR970100409A GR970100409A (el) 1996-10-30 1997-10-29 Βελτιωσεις στην προληψη του καρκινου του μαστου και σε σχεση με αυτην

Country Status (44)

Country Link
US (2) US6303634B1 (el)
EP (3) EP0839533A1 (el)
JP (2) JPH10147530A (el)
CN (2) CN1182591A (el)
AP (1) AP971A (el)
AR (2) AR010538A1 (el)
AT (2) ATE239475T1 (el)
AU (3) AU5005197A (el)
BE (2) BE1011381A5 (el)
BG (1) BG63841B1 (el)
BR (1) BR9712703A (el)
CA (2) CA2219070C (el)
CH (2) CH691847A5 (el)
CZ (2) CZ300261B6 (el)
DE (2) DE69721692T2 (el)
DK (2) DK0839532T3 (el)
EA (2) EA006083B1 (el)
EE (1) EE03663B1 (el)
ES (4) ES2135343A1 (el)
FR (2) FR2756490B1 (el)
GB (3) GB2318734B (el)
GE (1) GEP20032910B (el)
GR (2) GR970100409A (el)
HK (1) HK1010495A1 (el)
HU (2) HUP9701777A3 (el)
IE (2) IE970773A1 (el)
IL (2) IL122026A0 (el)
IS (1) IS5035A (el)
IT (2) ITMI972434A1 (el)
LU (2) LU90158B1 (el)
LV (1) LV12353B (el)
MY (1) MY121623A (el)
NL (2) NL1007387C2 (el)
NO (2) NO974973D0 (el)
NZ (1) NZ329042A (el)
PT (2) PT1369115E (el)
RO (1) RO120813B1 (el)
SG (2) SG83672A1 (el)
SI (3) SI0839532T1 (el)
SK (1) SK287047B6 (el)
TR (1) TR199900951T2 (el)
UA (1) UA46762C2 (el)
WO (2) WO1998018325A1 (el)
YU (1) YU42397A (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0674903A1 (en) * 1994-03-02 1995-10-04 Eli Lilly And Company Raloxifene for inhibiting bone loss and lowing serum cholesterol
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0674903A1 (en) * 1994-03-02 1995-10-04 Eli Lilly And Company Raloxifene for inhibiting bone loss and lowing serum cholesterol
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"FIRST PHASE III RESULTS WITH RALOXIFENE", DATABASE FILE 129, PHIND; DIALOG INFORMATION SERVICES; AN=540210, 13 June 1997 (1997-06-13), pages 17, XP002054373 *
"MARKET ANALYSIS FROM DECISION RESOURCES: BREAST CANCER", DATABASE FILE 187, FDC REPORTS; DIALOG INFORMATION SERVICES, AN=1249, vol. 1, no. 4, 1 April 1996 (1996-04-01), XP002054375 *
M.A. ANZANO ET AL.: "CHEMOPREVENTION OF MAMMARY CARCINOGENESIS IN THE RAT: COMBINED USE OF RALOXIFENE AND 9-CIS-RETINOIC ACID", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 88, no. 2, January 1996 (1996-01-01), pages 123 - 125, XP002054376 *
V.C. JORDAN ET AL.: "ALTERNATE ANTIESTROGENS AND APPROACHES TO THE PREVENTION OF BREAST CANCER", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 58, no. S.22, 1995, pages 51 - 57, XP002054374 *

Also Published As

Publication number Publication date
AR010538A1 (es) 2000-06-28
CN1182590A (zh) 1998-05-27
IT1298470B1 (it) 2000-01-10
CA2219070C (en) 2007-12-18
IL122025A (en) 2003-01-12
JPH10147530A (ja) 1998-06-02
DE69721692T2 (de) 2004-03-25
FR2755014B1 (fr) 1999-02-05
TR199900951T2 (xx) 1999-07-21
AU4364897A (en) 1998-05-07
CZ300261B6 (cs) 2009-04-01
EP1369115A1 (en) 2003-12-10
HUP9701778A2 (hu) 1999-01-28
NL1007386C2 (nl) 1998-05-14
ATE338551T1 (de) 2006-09-15
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
BG63841B1 (bg) 2003-03-31
NO322468B1 (no) 2006-10-09
LV12353A (lv) 1999-10-20
SK287047B6 (sk) 2009-10-07
CZ341297A3 (cs) 1998-05-13
BE1011381A5 (fr) 1999-08-03
AP971A (en) 2001-05-30
NO974972L (no) 1998-05-04
IE970773A1 (en) 2000-02-09
DE69721692D1 (de) 2003-06-12
LV12353B (en) 2000-02-20
US20020019418A1 (en) 2002-02-14
ATE239475T1 (de) 2003-05-15
ES2135342A1 (es) 1999-10-16
SI0839532T1 (en) 2003-10-31
YU42397A (sh) 2000-10-30
GEP20032910B (en) 2003-03-25
EA006083B1 (ru) 2005-08-25
GB9722796D0 (en) 1997-12-24
PT1369115E (pt) 2006-12-29
EE9900162A (et) 1999-12-15
EP0839532B1 (en) 2003-05-07
CN1182591A (zh) 1998-05-27
NZ329042A (en) 1999-08-30
AR013864A1 (es) 2001-01-31
DK1369115T3 (da) 2007-01-02
SI1369115T1 (sl) 2006-12-31
SG83672A1 (en) 2001-10-16
ES2135343A1 (es) 1999-10-16
HK1010495A1 (en) 1999-06-25
US6303634B1 (en) 2001-10-16
ITMI972433A1 (it) 1999-04-29
SG72765A1 (en) 2000-05-23
NO974973D0 (no) 1997-10-28
GB2318733A (en) 1998-05-06
UA46762C2 (uk) 2002-06-17
ES2197312T3 (es) 2004-01-01
DK0839532T3 (da) 2003-08-25
MY121623A (en) 2006-02-28
JPH10147529A (ja) 1998-06-02
BR9712703A (pt) 1999-10-26
CA2219377A1 (en) 1998-04-30
LU90157B1 (fr) 1998-06-02
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
EP1369115B1 (en) 2006-09-06
IS5035A (is) 1999-04-27
EA002054B1 (ru) 2001-12-24
DE69736644D1 (de) 2006-10-19
EP0839532A1 (en) 1998-05-06
EE03663B1 (et) 2002-04-15
CH693820A5 (fr) 2004-02-27
GR970100409A (el) 1998-06-30
BG103369A (en) 2000-05-31
IL122026A0 (en) 1998-03-10
AU5005697A (en) 1998-05-22
WO1998018325A1 (en) 1998-05-07
MX9708341A (es) 1998-08-30
RO120813B1 (ro) 2006-08-30
CH691847A5 (fr) 2001-11-15
HUP9701778A3 (en) 1999-06-28
EA199900431A1 (ru) 1999-10-28
IE970772A1 (en) 2000-02-09
NL1007387C2 (nl) 1998-05-14
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
ES2135342B1 (es) 2000-05-16
BE1011382A5 (fr) 1999-08-03
WO1998018449A1 (en) 1998-05-07
PT839532E (pt) 2003-09-30
FR2756490B1 (fr) 2003-06-20
IL122025A0 (en) 1998-03-10
EP0839533A1 (en) 1998-05-06
GB9722801D0 (en) 1997-12-24
GB2318734B (en) 1999-12-01
ES2271476T3 (es) 2007-04-16
AU731388B2 (en) 2001-03-29
AP9901494A0 (en) 1999-03-31
DE69736644T2 (de) 2007-10-25
FR2756490A1 (fr) 1998-06-05
ITMI972434A1 (it) 1999-04-29
GB2318734A (en) 1998-05-06
NO974972D0 (no) 1997-10-28
HUP9701777A3 (en) 1999-07-28
GB9911557D0 (en) 1999-07-21
FR2755014A1 (fr) 1998-04-30
AU5005197A (en) 1998-05-22
HUP9701777A2 (hu) 1999-06-28
SK55999A3 (en) 2000-06-12
SI20107A (sl) 2000-06-30
CZ341197A3 (cs) 1998-05-13
GR1003189B (el) 1999-09-01
CA2219070A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
GR970100408A (el) Μεθοδοι προληψεως του καρκινου του μαστου
GB9504216D0 (en) Magnetic stimulator for neuro-muscular tissue
AU1980995A (en) Methods and compositions for treatment of breast cancer
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
HUP0002760A3 (en) Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
GB9808764D0 (en) Magnetic stimulators for neuro-muscular tissue
EP0942742A4 (en) THERAPEUTIC COMPOSITIONS FOR CANCER TREATMENT
EP1007535A4 (en) METHOD AND PREPARATIONS FOR DIAGNOSTIC AND TREATMENT OF BREAST CANCER
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
GB2298370B (en) Magnetic stimulator for neuro-muscular tissue
IL127605A0 (en) Methods of cancer treatment using naaladase inhibitors
IL114119A0 (en) Compositions and methods for the treatment of tumors
EP1003516A4 (en) METHOD FOR THE ADMINISTRATION OF CAMPTOTHECIN COMPOSITIONS FOR CANCER TREATMENT WITH REDUCED SIDE EFFECTS
EP0918788A4 (en) BRCA1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING BREAST CANCER
ZA95508B (en) Use of flavolignans as adjuvants in tumour therapy
AU5434899A (en) Cancer treatment
PL328949A1 (en) Method of treatng excessive aggression
SG52807A1 (en) Shield for burial casket
GB9624800D0 (en) Methods of preventing breast cancer
RU1769885C (ru) Cпocoб лeчehия пapoдohtиta, ocлoжhehhoгo гипepecteзиeй tbepдыx tkaheй зубob
GB9024181D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
IL125682A0 (en) Droloxifene for prevention of breast cancer
IL103250A0 (en) Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
BG96320U (en) Compound for skin treatment

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees